Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.

Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- INCY

NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.

Levi & Korsinsky Reminds Incyte Corporation Investors of the Ongoing Investigation into Potential Violations of Securities Laws - INCY

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it will present at the 43rd Annual J. P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 am (PST). The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discov.

Incyte to Present at Upcoming Investor Conference

NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.

Incyte Corporation (INCY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.

Investors who lost money on Incyte Corporation should contact Levi & Korsinsky about an ongoing investigation - INCY

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.

Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - INCY

NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.

An Investigation Has Commenced on Behalf of Incyte Corporation Shareholders. Contact Levi & Korsinsky to Discuss your INCY Losses

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Most recently in the ever-growing biotech industry , investors are musing over potential changes to the sector after President-elect Donald Trump picked Martin “Marty” Makary to be the U.S. Food and Drug Administration's (FDA) next commissioner, and Robert F.

Biotech Roundup: 3 Stocks to Watch

NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Incyte Corporation (INCY)

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH24--Late-Breaking Tafasitamab (Monjuvi®) Data Demonstrate Significantly Improved Progression-Free Survival in Relapsed or Refractory Follicular Lymphoma.

Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma

NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.

INCY ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Incyte Corporation

INCY's phase III study, evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer, meets primary and secondary endpoints.

Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals

Exelixis

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investors?

EXEL or INCY: Which Is the Better Value Stock Right Now?

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in NSCLC.

Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.

ATTENTION Incyte Corporation Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.

INCY STOCK ALERT: Levi & Korsinsky Notifies Incyte Corporation Investors of an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.

Incyte Corporation Being Investigated on Behalf of Incyte Corporation Investors. Contact Levi & Korsinsky For Details.

NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.

Lost Money on Incyte Corporation(INCY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Why Is Incyte (INCY) Up 2.1% Since Last Earnings Report?

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will now present at Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 8:00 a.m. The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days. About Incyte A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, develop.

Incyte Announces Updated Presentation Time for Upcoming Investor Conference

NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.

INCY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Incyte Corporation investment

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH24--Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting.

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

NEW YORK, NY / ACCESSWIRE / November 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Incyte Corporation ("Incyte Corporation") (NASDAQ:INCY) concerning possible violations of federal securities laws. On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to "the observation of certain in vivo preclinical toxicology findings.

ATTENTION Incyte Corporation Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights

INCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries.

News for Incyte Stock (INCY)